Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial.
Ajar KocharAnne S HellkampYuliya LokhnyginaW Schuyler JonesRichard C BeckerScott D BerkowitzGünter BreithardtKeith A A FoxJonathan L HalperinGraeme J HankeyKenneth W MahaffeyChristopher C NesselDaniel E SingerJonathan P PicciniManesh R PatelPublished in: Clinical cardiology (2018)
Patients with CD in ROCKET AF had similar risk of stroke/SE compared with patients without CD. Additionally, there was no interaction between CD and the treatment effect of rivaroxaban or warfarin for stroke prevention or safety endpoints.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- direct oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- heart failure
- end stage renal disease
- percutaneous coronary intervention
- ejection fraction
- nk cells
- chronic kidney disease
- prognostic factors
- clinical trial
- venous thromboembolism
- study protocol
- coronary artery disease
- patient reported outcomes
- patient reported
- phase iii
- blood brain barrier
- smoking cessation